Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation
Open Access
- 1 May 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 28 (5) , 1015-1021
- https://doi.org/10.1161/01.str.28.5.1015
Abstract
Background and Purpose The results of a large prospective randomized trial have shown the efficacy of oral anticoagulation in the secondary prevention of major vascular events in patients with nonrheumatic atrial fibrillation (NRAF); less well established is the role of antiplatelet agents. The present study compared the effects of indobufen, a reversible inhibitor of platelet cyclooxygenase, with those of warfarin in this setting.Keywords
This publication has 19 references indexed in Scilit:
- Optimal Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Recent Cerebral IschemiaNew England Journal of Medicine, 1995
- Drugs and Surgery in the Prevention of Ischemic StrokeNew England Journal of Medicine, 1995
- Atrial fibrillation, stroke, and antithrombotic treatmentAmerican Heart Journal, 1994
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic riskThrombosis Research, 1987
- Cardiogenic Brain EmbolismArchives of Neurology, 1986
- Inhibition of platelet function with indobufen: Correlation with plasma drug levelThrombosis Research, 1985
- “Proving the null hypothesis” in clinical trialsControlled Clinical Trials, 1982
- Epidemiologic assessment of chronic atrial fibrillation and risk of strokeNeurology, 1978
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958